Preclinical Drug Development Miss Sirikan Nawapan.

Slides:

Advertisements

Similar presentations

§ 1.10 Properties of the Real Number System. Angel, Elementary Algebra, 7ed 2 Commutative Property Commutative Property of Addition If a and b represent.

Advertisements

Slide 1 Insert your own content. Slide 2 Insert your own content.

MULTIPLYING MONOMIALS TIMES POLYNOMIALS (DISTRIBUTIVE PROPERTY)

Analgesic ACM 7/29/021 Time-Specific Measurements vs. Time-Weighted Average for Pain in Chronic and Acute Analgesia Trials Laura Lu, Ph.D Office of Biostatistics,

Inhibition of Poly (ADP-Ribose) Polymerase (PARP) by ABT-888 in Patients With Advanced Malignancies: Results of a Phase 0 Trial Shivaani Kummar, MD National.

Addition 1’s to 20.

Bottoms Up Factoring. Start with the X-box 3-9 Product Sum

X-box Factoring. X- Box 3-9 Product Sum Factor the x-box way Example: Factor 3x 2 -13x (3)(-10)= x 2x 3x 2 x-5 3x +2.

1 Mechanism Testing of the Drug (Modified Megestrol) Mr.Pasavi Ratchapongsirikul.

Novel Drug Design Modified Megestrol by Group II.

Preclinical – Animal Study

Approval of Natural Chemopreventive Product. Scope of The Study Preclinical evaluation (In vivo)Preclinical evaluation (In vivo) –Toxicity testing  Acute.

1 11/8/00 Pharmacology of Tacrolimus Ointment William Fitzsimmons, Pharm.D. Vice President Drug Development Project Management Fujisawa Healthcare, Inc.

Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery & Therapeutics Altogen Labs 4020 S Industrial Dr Suite.

Nonclinical Perspective on Initiating Phase 1 Studies for Small Molecular Weight Compounds John K. Leighton, PH.D., DABT Supervisory Pharmacologist Division.

Isosteviol derivatives induced apoptosis in Human lung cancer via targeting MEK/MAPK pathway: An in vitro and in vivo study Ahmed M Malki 1,,PhD Stephen.

Laboratory toxicology. Toxicological methods In vitro –Cell cultures –Cell-free systems –Mechanistic In vivo (lab animals) –Acute –Subchronic –Chronic.

Pre-clinical studies  The animal model selected to perform the preclinical studies.  The protocol of vaccination  Evaluating the safety, immunogenicity.

Toxic effects Acute / chronic Reversible / irreversible Immediate / delayed Idiosyncratic - hypersensitivity Local / systemic Target organs.

第三章 Survivin siRNA nano particles are capable of inhibiting liver cancer cell growth both in vitro and in vivo Suoqin Tang,MD, Kuiyao Qu,MD, Yi Zhang,MD.

Section I General principle of Pharmacology. Where can you get information about general principle of Pharmacology?  Text books:  Katzung, Basic and.

A B PC9 PC9/gef B4 Supplementary Figure S1

 Chemotherapy is a common strategy used to kill cancer cells.  However toxicity of chemotherapy drugs to normal cells limits their application.

In Vitro and In Vivo Studies of Non-Platinum-Based Halogenated Compounds as Potent Antitumor Agents for Natural Targeted Chemotherapy of Cancers Qing-Bin.

Xiaoyan Wu, M. D. , Ph. D. , Peili Chen, M. D. , Ph. D. , Stephen T

Enhanced Sensitivity to Sunitinib by Inhibition of Akt1 Expression in Human Castration- resistant Prostate Cancer PC3 Cells Both In Vitro and In Vivo

Δ-Tocotrienol treatment is more effective against hypoxic tumor cells than normoxic cells: potential implications for cancer therapy Akira Shibata, Kiyotaka.

A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature Brandon Kats.

A Novel Cinnamide YLT26 Induces Breast Cancer Cells Apoptosis via ROS-Mitochondrial Apoptotic Pathway in Vitro and Inhibits.

Saikosaponin-D Enhances Radiosensitivity of Hepatoma Cells under Hypoxic Conditions by Inhibiting Hypoxia-Inducible Factor-1α Cell Physiol Biochem 2014;33:37-51.

Corresponding author:

Fig. 6. Knockdown of TCF-4 inhibits TCTP-induced glioma cell proliferation in vitro and in vivo. (A) TCF-4 was knocked down in U-251/TCTP and H-4/TCTP.

The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib Yiyu Zou, PhD, Yi-He.

An Introduction to Medicinal Chemistry 3/e

Cyclin-Dependent Kinase 2 Promotes Tumor Proliferation and Induces Radio Resistance in Glioblastoma Jia Wang, Tong Yang, Gaofeng Xu, Hao Liu, Chunying.

Volume 145, Issue 2, Pages (August 2013)

MET Tyrosine Kinase Inhibitor Crizotinib (PF ) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations

Concurrent Treatment with Anti-DLL4 Enhances Antitumor and Proapoptotic Efficacy of a γ-Secretase Inhibitor in Gastric Cancer Muxing Kang, Yaoyi Zhang,

Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.

C-kit Inhibition by Imatinib Mesylate Attenuates Progenitor Cell Expansion and Inhibits Liver Tumor Formation in Mice Belinda Knight, Janina E.E. Tirnitz–Parker,

Pegylated arginase I: a potential therapeutic approach in T-ALL

Volume 21, Issue 2, Pages (February 2013)

Volume 19, Issue 1, Pages (January 2017)

Volume 139, Issue 4, Pages (October 2010)

The Zinc Ionophore PCI-5002 Radiosensitizes Non-small Cell Lung Cancer Cells by Enhancing Autophagic Cell Death Kwang Woon Kim, PhD, Christina K. Speirs,

Volume 140, Issue 1, Pages (January 2011)

Brian Hutzen, Chun-Yu Chen, Pin-Yi Wang, Les Sprague, Hayley M

Antisense Oligonucleotides Targeting Y-Box Binding Protein-1 Inhibit Tumor Angiogenesis by Downregulating Bcl-xL-VEGFR2/-Tie Axes Kiyoko Setoguchi, Lin.

The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib Yiyu Zou, PhD, Yi-He.

Volume 7, Issue 3, Pages (March 2005)

Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.

Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non– Small Cell Lung Cancer Xenograft Models Josephine Hai, PhD, Shingo Sakashita,

Volume 145, Issue 2, Pages (August 2013)

Volume 142, Issue 7, Pages e2 (June 2012)

by Kamira Maharaj, John J

miR-124 Inhibits Lung Tumorigenesis Induced by K-ras Mutation and NNK

Molecular Therapy - Nucleic Acids

Green Tea Polyphenol Epigallocatechin-3-Gallate Suppresses Collagen Production and Proliferation in Keloid Fibroblasts via Inhibition of the STAT3-Signaling.

Induction of Angiopoietin-2 gene expression by COX-2: A novel role for COX-2 inhibitors during hepatocarcinogenesis Shinji Tanaka, Jack R. Wands, Shigeki.

Targeting ubiquitin-activating enzyme induces ER stress–mediated apoptosis in B-cell lymphoma cells by Scott Best, Taylor Hashiguchi, Adam Kittai, Nur.

Volume 12, Issue 4, Pages (July 2015)

Volume 18, Issue 3, Pages (March 2010)

Molecular Recognition and In-Vitro-Targeted Inhibition of Renal Cell Carcinoma Using a DNA Aptamer Hui Zhang, Zhibo Wang, Lin Xie, Yibin Zhang, Tanggang.

Molecular Therapy - Nucleic Acids

Protracted temozolomide (TMZ) treatment leads to acquired TMZ resistance in glioblastoma (GBM) cells in vivo. Protracted temozolomide (TMZ) treatment leads.

N-3 PUFAs promote endometrial cancer cell apoptosis in vitro and in vivo. n-3 PUFAs promote endometrial cancer cell apoptosis in vitro and in vivo. HEC-1-A.

Antitumor effects of celastrol in vitro and in vivo.

Presentation transcript:

Preclinical Drug Development Miss Sirikan Nawapan

Objectives To evaluate the anticancer properties of this modified drug by studying cell proliferation tumor volumetric apoptosis DNA fragment To provide the evidence for supporting the safety of use in patient treatment

Components of Preclinical Drug Development 1. In vitro study : Cytotoxicity assay 2. In vivo study : Pharmacokinetic study : Animal testing : Toxicity test

In vitro study Objectives To study the effectiveness of the drug on the growth of HepG2 cells and to provide the appropriate concentration using in vivo study.

of in vitro study Components of in vitro study 1.Preparation of HepG2 cells 2.Cytotoxicity test 2.1 Dose dependent inhibition 2.2 Time dependent inhibition 3.Determination of cell cycle and apoptosis

Preparation of HepG2 cells line cDNAs contain the full-length ER and ER5 pcDNA3 Transfect in to HepG2 cells line Introduce cDNA into pcDNA3

HepG2 + ER 5 HepG2 + ER α MTT assay stock solution con c1 con c4 con c3 con c2 con c5 con trol Cytotoxicity test

IC 50 Dose dependent inhibition of HepG2 cells by modified megestrol

Time dependent inhibition of HepG2 cells by modified megestrol

Cell suspensions and Propidium Iodide Staining Determination of Cell Cycle and Apoptosis HepG2 cell lines Analyzed by Flow cytometry ApopAlert LM-PCR Ladder Assay kit +

In vivo study Objective To study the efficacy and toxicity of the modified drug in nude mice. Components of in vivo study 1. Pharmacokinetic study 2. Animal testing 3. Toxicity test

Pharmacokinetic study Control Male Female Blood, Urine, Feces samples High Performance Liquid Chromatography (HPLC) 14 C-Radiolabeled Modified Megestrol

Qualitative Distribution Study MaleFemalePregnant Sacrificed and Sagittal Section (30 m) Whole Body Autoradiography

Animal testing HepG2 + vER Modified Megestrol male female control Vehicle

Animal Testing Endpoints Week Tumor Vol (% Orig Vol) Body Weight (g) % of survivors body weight (g) = total weight (g) – tumor volume(cm 3 )

Toxicity Test Test 1:The LD 50 determination 5 doses and 6 mices/sex/dose Test 2:The LD50 determination (finely tune) 5 doses and 6 mices/sex/dose Test 3:Acute toxicity test 3 dose of test 2 and 6 mices/sex/dose Test 4:Subchronic toxicity test 1/20 dose of test 2,10 mices/sex/dose Test 5: Chronic toxicity test No-effect dose in test 4,10 mices/sex/dose

Summary Tested drugIn vitroIn vivoClinical trials IC 50 Phase I staring dose -Anticancer properties of drug -Toxicity testing

THE END